J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM
Rangering i aksjer
#3892
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai,... J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Aksjekurs
$26.58
Sist synkronisert: 2026-07-23
Markedsverdi
$4.24B
Endring (1 dag)
0.00%
Endring (1 år)
38.14%
Land
IN
Handel J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Kategori
Healthcare
Inntekter for J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Inntekter i Mar 2026 TTM: $105.10M
Ifølge J. B. Chemicals & Pharmaceuticals Limited sine nyeste økonomiske rapporter er selskapets nåværende resultat $105.10M. I 2024 hadde selskapet et resultat på $90.13M, en økning sammenlignet med resultatet i 2023, som var $67.56M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for J. B. Chemicals & Pharmaceuticals Limited fra 2005 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $105.10M | 1.29% |
| 2025 | $103.76M | 15.12% |
| 2024 | $90.13M | 33.40% |
| 2023 | $67.56M | 1.58% |
| 2022 | $66.51M | -18.43% |
| 2021 | $81.54M | 76.06% |
| 2020 | $46.31M | 12.06% |
| 2019 | $41.33M | 38.74% |
| 2018 | $29.79M | -15.99% |
| 2017 | $35.46M | 12.49% |
| 2016 | $31.52M | 35.13% |
| 2015 | $23.33M | 59.89% |
| 2014 | $14.59M | -23.47% |
| 2013 | $19.06M | -88.54% |
| 2012 | $166.34M | 348.33% |
| 2011 | $37.10M | 12.53% |
| 2010 | $32.97M | 351.68% |
| 2009 | $7.30M | -33.14% |
| 2008 | $10.92M | -33.49% |
| 2007 | $16.41M | -11.60% |
| 2006 | $18.57M | 22.45% |
| 2005 | $15.16M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 1,578.98% |
IN
|
